

Supplementary Material

Figure S1. A characteristic NMR spectrum acquired with the CPMG pulse sequence of the serum blood is displayed in with annotations on the identified metabolites (1. Valine, ((2S)-2-amino-3-methylbutanoic acid), 2.Lactate ((2S)-2-hydroxypropanoic acid), 3.Glucose, ((2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol), 4.Leucine ((2S)-2-amino-4-methylpentanoic acid), 5.Isoleucine ((2S,3S)-2-amino-3-methylpentanoic acid), 6.Alanine ((2S)-2-aminopropanoic acid), 7.Creatine (2-(N-methylcarbamimidamido)acetic acid), 8.1-Methyl histidine (1-Methyl histidine), 9.Tyrosine ((2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid), 10.Formic acid (Formic acid), 11.Phenyl alanine Phenylalanine ((2S)-2-amino-3-phenylpropanoic acid), 12.n-Acetylglutamine ((2S)-4-carbamoyl-2-acetamidobutanoic acid), 13. Glutamine ((2S)-2-amino-4-carbamoylbutanoic acid), 14. Acetoacetate (3-oxobutanoic acid), 15. Glutamic acid ((2S)-2-aminopentanedioic acid), 16.Acetic acid (Acetic acid), 17.Acetone (propan-2-one), 18.Citric acid (2-hydroxypropane-1,2,3-tricarboxylic acid), 19.Choline ((2-hydroxyethyl)trimethylazanium), 20.Creatinine (2-imino-1-methylimidazolidin-4-one), 21.Phosphorylcholine ([2-(trimethylazaniumyl)ethoxy]phosphonic acid), 22.Methylamine (methanamine), 23. Dimethylamine (Dimethylamine), 24.L-Aspartic acid ((2S)-2-aminobutanedioic acid), 25.L-Asparagine ((2S)-2-amino-3-carbamoylpropanoic acid), 26.3-Hydroxybutyric acid ((3R)-3-hydroxybutanoic acid), 27. Glycine (2-aminoacetic acid), 28.Betaine ((carboxymethyl)trimethylazanium), 29.2-Hydroxybutyric acid ((2S)-2-hydroxybutanoic acid), 30.Isobutyric acid (2-methylpropanoic acid), 31.L-Threonine ((2S,3R)-2-amino-3-hydroxybutanoic acid), 32. D-Lysine, ((2R)-2,6-diaminohexanoic acid))




Figure S2. PCA model, N=81; $R^2X(\text{cum})= 0.63$; $Q^2(\text{cum})=0.58$. Green squares =samples with thyroid disorder & blue circles = Control samples.




Figure S3. OPLS-DA model, A=1+1; N=76; R²X(cum)= 0.59; R²Y(cum)=0.45; Q²(cum)=0.33. Green squares=samples with thyroid disorder & blue circles= Control samples.




Figure S4. Box plots regarding the meat intake of the participants




Figure S5. A typical is depicted standard ^1H NMR spectrum of colostrum with the NOESY-PRESAT sequence (1. Leucine ((2S)-2-amino-4-methylpentanoic acid), 2. Isoleucine ((2S,3S)-2-amino-3-methylpentanoic acid), 3. fucosyl moieties , 4. Lactate ((2S)-2-hydroxypropanoic acid), 5. Threonine ((2S,3R)-2-amino-3-hydroxybutanoic acid, 6. Alanine ((2S)-2-aminopropanoic acid), 7. Ch3GlcNaC (Ch3GlcNaC), 8. citric acid (2-hydroxypropane-1,2,3-tricarboxylic acid), 9. Choline ((2-hydroxyethyl)trimethylazanium), 10. o-phosphocholine ([2-(trimethylazaniumyl)ethoxy]phosphonic acid), 11. glycerophosphocholine((2-{[(2R)-2,3-dihydroxypropyl phosphono]oxy}ethyl)trimethylazanium), 12. Cytidine (4-amino-1-[2(R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one), 13. Lactose ((2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-{[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl) oxan-3-yl]oxy}oxane-3,4,5-triol), 14. Tyrosine ((2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid), 15. L-phenyl alanine ((2S)-2-amino-3-phenylpropanoic acid), 16. τ -merhyl histidine (τ -merhyl histidine), 17. formic acid (formic acid))




Figure S6. PCA model, N=84; $R^2X(\text{cum})= 0.44$; $Q^2(\text{cum})=0.39$. Green squares =samples with thyroid disorder & blue circles = Control samples.




Figure S7. OPLS-DA model, A=1+1; N=78; R²X(cum)= 0.29; R²Y(cum)=0.65; Q²(cum)=0.49. Green squares=samples with thyroid disorder & blue circles= Control samples.




Figure S8. (A) ROC graph AUC (no)= 0.72 and AUC(thyr)=0.85 (B) permutation testing for the OPLS-DA model in Figure 1 and (C) ROC graph AUC (no)= 0.72 and AUC(thyr)=0.79 (D) permutation testing for the OPLS-DA model Figure 3, respectively; (E) ROC graph AUC (no)= 0.90 and AUC(thyr)=0.90 (F) permutation testing for the OPLS-DA model in Figure S3 and (G) ROC graph AUC (no)= 0.78 and AUC(thyr)=0.96 (H) permutation testing for the OPLS-DA model Figure S7, respectively.




Figure S9 Box plots for fruit intake of the participants




Figure S10 ROC graph with the AUC value for discriminant metabolites in the serum substrate. 1. Valine ((2S)-2-amino-3-methylbutanoic acid), 2. Glycerol (propane-1,2,3-triol), 3. L-phenyl alanine (2S)-2-amino-3-phenylpropanoic acid), 4. Tyrosine ((2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid), 5. Alanine ((2S)-2-aminopropanoic acid), 6. Methanol, 7. Acetic acid, 8. Cholesterol-VLDL ((3 β)-cholest-5-en-3-ol-VLDL), 9. Unsaturated lipid, 10. 1-Methyl histidine, 11. methionine (2-amino-4-(methylthio)butanoic acid), 12. LDL2/VLDL2 , 13. n-acetylated glycoproteins




Figure S11 ROC graph with AUC for discriminant metabolites in the colostrum substrate. 1. Fucosyl moieties, 2. Threonine ((2S,3R)-2-amino-3-hydroxybutanoic acid), 3. o-phosphocholine (2-(trimethylazaniumyl) ethoxy]phosphonic acid), 4. Lactate ((2S)-2-hydroxypropanoic acid), 5. Glycerol-phosphocholine ((2-{{(2R)-2,3-dihydroxypropyl phosphono}oxy}ethyl)trimethylazanium), 6. Choline (2-hydroxyethyl)trimethylazanium)




Table S1 A summary on the samples analyzed and their characteristics

class	Nationality	Parity	Maternal Age	Weight_M_Start	Weight_M_End	Height	BMI before	BMI after	Gestational Age	Birth Mode	Sex	Weight Infant	Cente	Diabetes	Hypertension	Other Pathology	Pharmac	Meat (portion/week)	Fish (portion/week)	Dairy (portion/week)	Legumes (portion/week)	Eggs (portion/week)	Smoking before Birth (perday)	Smoking Gestation (per day)	Peculiarity	Allergy	Fruit	Vegetables	Sweets	fT4 (ng/dl)	TSH (mIU/L)	
ctr	greek	3	40	54	64	1,59	21,36	25,32	294	NM	male	3350	29	no	no	glaukoma	Fe Ca folic	2	1	7	1	2	0	0	no	no	2	7	1	1,2	1,9	
ctr	kazachstan	1	28	62	85	1,63	23,34	31,99	273	CS	male	3480	65	no	no	Iron deficiency anemia	Fe Ca Mg folic	2	0,5	7	2	2	0	0	no	no	7	7	2		2,1	
ctr	greek	2	34	68	82	1,68	24,09	29,05	280	NM	female	3750	59	no	no	no	Fe Ca folic	3	1	7	1	0,5	0	0	no	no	7	7	1	1,1	2	
ctr	albanian	1	24	75	93	1,65	27,55	34,16	269	CS	male	2630	4	no	no	no	Fe Ca folic	1	0	4	2	0	20	3	nofish, no egg	no	7	7	2	0,9	1,8	
ctr	rumanian	2	32	65	80	1,7	22,49	27,68	277	NM	female	3430	52	no	no	no	Fe Ca folic	3	1	7	1	1	0	0	no	no	0	7	1	0,85	1,9	
ctr	greek	2	33	96	100	1,7	33,22	34,60	280	CS	female	3740	65	no	no	medit anemia	Fe Ca folic	3	2	7	2	1	0	0	no	no	7	7	2	1,5	2,2	
ctr	vietnam	1	27	47	65	1,55	19,56	27,06	259	NM	male	3460	97	no	no	no	Fe Ca	3	1	7	2	2	0	0	no	no	14	7	2	0,9	1,7	
ctr	greek	2	39	48	62	1,6	18,75	24,22	265	CS	female	2570	18	no	no	no	Fe Ca	1	0,5	0	3	2	10	0	nodairy	no	3	7	2	1,2	2,3	
ctr	albanian	1	27	56	65	1,57	22,72	26,37	255	CS	female	2160	10	no	no	no	Fe Ca folic	1	0	3	4	1	0	0	nofish	no	2	3	1	0,8	2,1	
ctr	greek	3	25	52	58	1,6	20,31	22,66	280	NM	male	2770	4	no	no	no	Fe Ca innohep	2	0	14	1	0	0	0	nofish, no egg	no	3	7	2	0,87	2,34	
ctr	russian	2	29	95	110	1,72	32,11	37,18	272	NM	female	4120	94	no	no	no	Fe Ca Mg	4	0	7	0,5	3	0	0	nofish	no	14	21	5	1,24	2,05	
ctr	albanian	2	32	85	92	1,6	33,20	35,94	273	CS	male	3160	33	no	no	no	Fe Ca folic	1	1	7	2	0,5	0	0	no	no	7	14	0	0,95	2,1	
ctr	greek	1	37	67	73	1,73	22,39	24,39	250	NM	male	2670	43	no	no	no	Fe salospir	2	2	7	1	4	10	3	no	no	3	7	3	1,1	1,9	
ctr	syrian	1	17	57	68	1,63	21,45	25,59	280	NM	male	3220	33	no	no	no	Fe Ca folic	1	0	7	3	2	0	0	nofish	no	7	14	3	0,7	2,4	
ctr	moldavian	2	29	65	80	1,7	22,49	27,68	278	NM	male	3280	25	no	no	no	Fe Ca	1	0,5	0	3	1	0	0	nodairy	no	7	14	3	0,8	1,9	
ctr	rumanian	1	24	70	74	1,65	25,71	27,18	271	NM	male	2750	7	no	no	no	Fe Ca folic	3	0,5	7	0,5	3	0	0	no	no	7	7	1	1,3	2,1	
ctr	greek	1	25	60	87	1,65	22,04	31,96	282	CS	male	3790	75	no	no	no	Fe Ca folic	4	1	7	0	0	10	0	nolegumes	no	7	7	7	1,05	2	
ctr	greek	2	41	61	63	1,6	23,83	24,61	275	NM	female	2880	15	no	no	no	Fe Ca	3	1	0	3	0	0	0	nodairy, no egg	no	3	no	7	0,95	2,1	
ctr	greek	2	41	61	63	1,6	23,83	24,61	275	NM	female	2880	15	no	no	no	Fe Ca	3	1	0	3	0	0	0	nodairy, no egg	no	3	no	7	0,95	2,1	
ctr	albanian	1	28	57	67	1,6	22,27	26,17	282	NM	male	3790	79	no	no	no	Fe Ca folic	2	1	7	2	1	0	0	no	no	4	14	2	0,8	2	
ctr	albanian	2	27	45	65	1,5	20,00	28,89	273	CS	male	2770	17	no	no	no	Fe Ca	1	0,5	7	3	1	0	0	no	no	7	7	3	1,15	2,25	
ctr	albanian	2	23	53	57	1,57	21,50	23,12	284	CS	male	3510	65	no	no	no	Fe Ca			0											0,9	2,2
ctr	greek	3	33	80	96	1,7	27,68	33,22	290	CS	male	4000	65	όχι	no	no	Fe Ca	2	1	7	1	7	0	0	no	no	7	7	7	1,25	2,4	
ctr	greek	2	40	72	86	1,6	28,13	33,59	268	CS	male	3500	65	no	no	no	Fe Ca	3	1	7	1	3	2,86	0	no	no	7	7	1	0,85	2,3	
ctr	albanian	2	31	55	65	1,65	20,20	23,88	275	CS	male	3550	63	no	no	no	Fe Ca	7	2	2	1	2	0	0	no	no	7	7	7	1,1	2,1	
ctr	greek	1	37	59	73	1,71	20,18	24,96	273	NM	female	3420	70	no	no	multiple sclerosis	Fe Ca	7	2	7	1	2	0	0	no	no	5	7	7	1,05	2	
ctr	greek	2	39	78	85	1,7	26,99	29,41	267	CS	male	3390	51	οχι	no	no	Fe Ca	4	1	7	1	7	0	0	no	no	7	7	4	1,3	1,9	
ctr	greek	2	35	59	75	1,62	22,48	28,58	267	CS	female	2750	19	no	no	no	Fe Ca Mg folic	3	1	5	2	1	7	0	no	no	7	7	7	1,2	2,15	
ctr	greek	1	34	56	66	1,68	19,84	23,38	272	CS	male	3600	77	no	no	no	Fe Ca	3	1	7	2	3	2	0	no	no	7	7	0	1,4	2,3	

																									legumes						
thy	greek	1	37	53	67	1,58	21,23	26,84	276	CS	female	3170	54	GDM (insulin)	no	hypothy	Fe Ca folict4 insulin	2	1	7	1	0	10	0	no egg	no	7	7	1	0,53	3,1
thy	greek	1	42	62	78	1,63	23,34	29,36	271	CS	female	3180	54	GDM (insulin)	no	hypothy	t4 125 salospir innohep insulin	3	1	7	2	3	0	0	no	no	7	7	0	1,04	2,9
thy	greek	1	32	58	78	1,75	18,94	25,47	285	NM	female	3320	39	no	no	hypothy	Fe Ca t4 62	3	1	7	2	2	10	0	no	no	14	7	1	0,9	2,6
thy	greek	2	36	54	59	1,62	20,58	22,48	259	CS	female	2770	48	no	no	hypothy	Fe Ca t4 137	2	1	7	3	3	5	0	no	no	4	7	4	0,95	2,77
thy	greek	2	45	70	85	1,59	27,69	33,62	277	CS	female	3370	48	no	no	hypothy	Fe Ca folict4 125	1	2	4	1	2	0	0	no	no	7	14	0	1,2	3,8
thy	greek	1	24	60	76	1,65	22,04	27,92	266	CS	male	2430	2	no	no	hypothy	Fe Ca Mg t4 62	3	0,25	7	4	0	20	0	no egg	no	4	0,5	3	0,8	2,5
thy	greek	1	35	54	71	1,6	21,09	27,73	272	CS	female	2740	19	no	no	hyperthy	Fe Ca folic unimazole	2	0	7	1	7	7	0	no fish	no	7	2	4	0,7	3

Table S2 Summary of metabolites in both biofluids with a p-value < 0.005

Metabolite IUPAC (serum)	Metabolite (serum)	V	p.value	-LOG10(p)	FDR
propane-1,2,3-triol	glycerol	891	1,22E-10	9,9122	8,08E-08
unsaturated lipid	unsaturated lipid	91	1,96E-09	8,7075	1,98E-07
(3 β)-cholest-5-en-3-ol-VLDL	cholesterol-VLDL	134	2,06E-07	6,686	2,11E-06
2-aminopropanoic acid	alanine	664	0,009303	2,0314	0,029354
methanol	methanol	304	0,012492	1,9034	0,038257
LDL2/VLDL2	LDL2/VLDL2	108	1,42E-08	7,8473	2,84E-07
2-amino-3-(4-hydroxyphenyl)propanoic acid	tyrosine	805	4,83E-02	1,3162	8,99E-01
1-methylhistidine	1-methylhistidine	718	8,05E-03	2,0943	8,99E-01
2-amino-4-(methylsulfanyl)butanoic acid	methionine	793	3,86E-02	1,413	8,99E-01
2-amino-3-phenylpropanoic acid	L-phenylalanine	750	1,63E-02	1,7873	8,99E-01
Metabolite IUPAC (milk)	Metabolite (milk)	V	p.value	-LOG10(p)	FDR
Fucosyl moieties	Fucosyl moieties	129	2,91E-06	5,5364	0,00235
2-amino-3-hydroxybutanoic acid	threonine	148	1,55E-05	4,8084	0,00235
2-hydroxypropanoic acid	lactate	212	0,00139	2,857	0,037353
[2-(trimethylazaniumyl)ethoxy]phosphonic acid	0-phosphocholine	205	0,000916	3,0383	0,027568
(2-hydroxyethyl)trimethylazanium	choline	227	0,003224	2,4916	0,066046
(2-[(2R)-2,3-dihydroxypropyl phosphono]oxy]ethyl)trimethylazanium	glycerophosphocholine	224	0,002894	2,5385	0,059037

Table S3 Result from Pathway Analysis on the Serum samples

Pathway Name	Match Status	p	-log(p)	Holm p	FDR	Impact
Phenylalanine, tyrosine and tryptophan biosynthesis	2/ 4	1,045E-04	39.809	0.0087786	0.0087786	1.0
Phenylalanine metabolism	2/ 10	7,737E-04	31.114	0.064219	0.025056	0.35714
Aminoacyl-tRNA biosynthesis	3/ 48	8,949E-04	30.483	0.073378	0.025056	0.0
Ubiquinone and other terpenoid-quinone biosynthesis	1/9	0.04002	13.977	1.0	0.84042	0.0
Histidine metabolism	1/ 16	0.07019	11.537	1.0	0.98266	0.0
Glycerolipid metabolism	1/ 16	0.07019	11.537	1.0	0.98266	0.23676
Pyruvate metabolism	1/ 22	0.0954	10.205	1.0	1.0	0.06065
Glycolysis / Gluconeogenesis	1/ 26	0.11188	0.95125	1.0	1.0	0.02906
Galactose metabolism	1/ 27	0.11596	0.9357	1.0	1.0	0.0
Glyoxylate and dicarboxylate metabolism	1/ 32	0.13611	0.8661	1.0	1.0	0.0
Cysteine and methionine metabolism	1/ 33	0.1401	0.85357	1.0	1.0	0.10446
Tyrosine metabolism	1/ 42	0.17525	0.75635	1.0	1.0	0.13972

Table S4 Result from Pathway Analysis on the colostrum samples

Pathway Name	Match Status	p	-log(p)	Holm p	FDR	Impact
Glycerophospholipid metabolism	3/ 36	1,12E-04	39.523	0.009375	0.009375	0.08333
Glycine, serine and threonine metabolism	2/ 33	0.0042247	23.742	0.35065	0.17744	0.0
Valine, leucine and isoleucine biosynthesis	1/ 8	0.025574	15.922	1.0	0.71608	0.0
Ether lipid metabolism	1/ 20	0.062952	1.201	1.0	1.0	0.0
Pyruvate metabolism	1/ 22	0.069068	11.607	1.0	1.0	0.0
Glycolysis / Gluconeogenesis	1/ 26	0.081205	10.904	1.0	1.0	0.0
Aminoacyl-tRNA biosynthesis	1/ 48	0.14572	0.83649	1.0	1.0	0.0

Table S5 Resonance peak identification of 37 metabolites with the Metaboneer software in serum with report of their fold changes

Table S6 A summary of the identified metabolites

Metabolite	Metabolite (IUPAC)	Chemical shifts	Assignment	Multiplicity
Valine	(2S)-2-amino-3-methylbutanoic acid	0.99, 1.03	CH ₃ , CH ₃	d, d
Lactate	(2S)-2-hydroxypropanoic acid	1.33, 4.11	CH ₃ , CH	d, q
Glucose	(2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol	3.4-4.0, 5.23-	various, H1, CH	m, d
Leucine	(2S)-2-amino-4-methylpentanoic acid	0.96	d-CH ₃	d+d
Isoleucine	(2S,3S)-2-amino-3-methylpentanoic acid	0.93, 1.00	d-CH ₃ , b-CH ₃	t, d
Alanine	(2S)-2-aminopropanoic acid	1.47	CH ₃	d
Creatine	2-(N-methylcarbamimidamido)acetic acid	3.04, 3.93	CH ₃ , CH ₂	s, s
1-Methyl histidine,	1-methyl-L-histidine	7.06, 7.79	CH ₂ , CH ₂	s, s
Tyrosine	(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid	6.88, 7.17	CH, CH	dd, dd
Formic acid	Formic acid	8.45	CH	s
Phenyl alanine	(2S)-2-amino-3-phenylpropanoic acid	7.33, 7.43	H2 + H6, H3+H5	m, m
Glutamine	(2S)-2-amino-4-carbamoylbutanoic acid	2.44	half g-CH ₂	m
Acetoacetate	3-oxobutanoic acid	2.23	CH ₃	s
Glutamic acid	(2S)-2-aminopentanedioic acid	2.35	half g-CH ₂	m
Acetic acid	Acetic acid	1.92	CH ₃	s
Acetone	propan-2-one	2.24	CH ₄	s
Citric acid	2-hydroxypropane-1,2,3-tricarboxylic acid	2.53, 2.69	half CH ₂ , half CH ₂	d, d
Choline	(2-hydroxyethyl)trimethylazanium	3.21	N(CH ₃) ₃	s
Creatinine	2-imino-1-methylimidazolidin-4-one	3.05, 4.05	CH ₃ , CH ₂	s, s
Dimethylamine	Dimethylamine	2.9		s
L-Aspartic acid	(2S)-2-aminobutanedioic acid	2.68, 2.82, 3.90	half CH ₂ , half CH ₂ , CH	dd, dd, dd
L-Asparagine	(2S)-2-amino-3-carbamoylpropanoic acid	2.85, 2.95, 4.00	half β-CH ₂ , half β-CH ₂ , α-CH	m, m, dd
3-Hydroxybutyric acid	(3R)-3-hydroxybutanoic acid	2.30, 2.40	half α-CH ₂ , half α-CH ₂	m, m
Glycine	2-aminoacetic acid	3.55	CH ₂	s
Betaine	(carboxymethyl)trimethylazanium	3.28	CH ₂	s

L-Threonine	(2S,3R)-2-amino-3-hydroxybutanoic acid	1.33, 3.59, 4.25	$\gamma\text{-CH}_3$, $\alpha\text{-CH}$, $\beta\text{-CH}$	d, d, m
D-Lysine	(2R)-2,6-diaminohexanoic acid	1.68-1.75	d-CH ₂ , g-CH ₂	m, m
cholesterol-VLDL	(3 β)-cholest-5-en-3-ol-VLDL	0,72	R-CH 3	m
LDL2/VLDL2	LDL2/VLDL2	1.22-1.30	(CH ₂) _n /CH ₂ C H ₂ CH ₂ CO	m
unsaturated lipid	unsaturated lipid	5,15	-CH]CH-	m
glycerophosphocholine	(2-[(2R)-2,3-dihydroxypropyl phosphono]oxy}ethyltrimethylazanium	3.22, 3.68, 4.32	CH ₃ , NCH ₂ , OCH ₂ CH ₂	s, t, t
O-Phosphocholine	[2-(trimethylazanium yl)ethoxy]phosphonic acid	3,24		s